Daxibotulinumtoxina
Upper Limb Spasticity
Revance Therapeutics, Inc.protein_peptidePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Upper Limb Spasticity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tizanidine Icahn School of Medicine at Mount Sinai | Phase 4 | BB |
Xeomin® Ipsen | Phase 4 | BB |
Abbv-950 AbbVie | Phase 1 | CC |
Same molecule, other indications
Daxibotulinumtoxina is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →